Our FcγRIIIa-enhanced antibody was designed based on robust FcγRIIIa expression on NK cells and myeloid cells in tumor lesions and the correlation of expression with the therapeutic efficacy of trastuzumab (Fig. 1). Here, FCGR3A is linked to neoplasm.